Question 1

Does Aetna cover Wegovy?

Accepted Answer

Aetna covers Wegovy on Non-Medicare commercial plans under bulletin 4774-C UDR 08-2023 v2 (effective 05/01/2024). Adult initial criteria: patient must be >=18, have BMI >=30 (or BMI >=27 with one weight-related comorbidity), and have participated in a comprehensive weight-management program for at least 6 months prior to drug therapy. Initial approval is 7 months; continuation/reauthorization is 12 months and requires documented loss of at least 5% of baseline body weight (or maintained 5% loss). Pediatric (12-17): BMI in the 95th percentile or greater + 6-month program. Wegovy also has a separate cardiovascular risk-reduction pathway in 4774-C for patients with established CVD on guideline-directed management and therapy who do NOT have type 2 diabetes. CVS Caremark (Aetna's PBM, both CVS Health subsidiaries) designated Wegovy the PREFERRED commercial GLP-1 in July 2025 — most Aetna commercial books now step toward Wegovy. Quantity limits: 0.25-1 mg = 2 mL per 21 days; 1.7-2.4 mg = 3 mL per 21 days.

Question 2

Does Aetna cover Ozempic for weight loss?

Accepted Answer

Aetna covers Ozempic for type 2 diabetes per bulletin 2439-C UDR 05-2024 (last reviewed 10/27/2024). Initial PA requires the patient is NOT on stable GLP-1 maintenance >=3 months AND meets one of: (1) inadequate response, intolerance, or contraindication to metformin; (2) requires combination therapy AND has A1C >=7.5%; (3) eGFR <30 mL/min/1.73m^2; or (4) established cardiovascular disease. Continuation requires stable maintenance >=3 months AND demonstrated A1C reduction since starting GLP-1 therapy. Aetna Medicare Part D plans cover Ozempic for type 2 diabetes (NOT for off-label weight loss). Quantity limits vary by strength: 2 mg/1.5 mL = 1 pen per 21 days; 4 mg/3 mL and 8 mg/3 mL = 1 pen per 21 days. Verbatim MACE language in the bulletin: 'reduce the risk of major adverse cardiovascular events…in adults with type 2 diabetes mellitus and established cardiovascular disease.' For weight-loss-only use without a diabetes diagnosis, Aetna typically does not cover Ozempic, since the drug is FDA-approved only for type 2 diabetes (Wegovy is the obesity-indicated semaglutide).

Question 3

Does Aetna cover Zepbound?

Accepted Answer

Aetna covers Zepbound on Non-Medicare commercial plans per bulletin 6947-C P04-2025 (effective 07/01/2025), which supersedes the older 6192-C. Adult criteria: BMI >=30 OR BMI >=27 with one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia), plus participation in a comprehensive weight-management program for at least 6 months prior to drug therapy. Continuation requires documented >=5% baseline body-weight loss. Separate OSA pathway covers moderate-to-severe OSA in adults with obesity (AHI >=15 events/hour). CRITICAL CAVEAT: a separate Zepbound Exception bulletin 6981-A P04-2025 applies on plan-formulary codes ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC where Wegovy is the preferred step. CVS Caremark removed Zepbound from MOST commercial formularies effective July 2025 in favor of Wegovy as the single preferred GLP-1, so many Aetna commercial members now see Zepbound denials they did not see in 2024. Aetna Medicare Part D does NOT cover Zepbound for weight loss (statutory exclusion); may cover for OSA indication. Beginning 07/01/2026, only the Zepbound KwikPen formulation (NOT vials/single-dose pens) is available to MA-PD members via the CMS Medicare GLP-1 Bridge. Quantity limits all strengths: 2 mL (1 package of 4 pens) per 21 days; 6 mL (3 packages of 4 pens) per 63 days.

Question 4

Does Aetna cover Mounjaro?

Accepted Answer

Aetna covers Mounjaro for type 2 diabetes per bulletin 5468-C UDR 05-2024 (last reviewed 10/27/2024). Initial PA verbatim: 'The patient has NOT been receiving a stable maintenance dose of the requested drug for at least 3 months and ONE of the following criteria are met' — either metformin inadequacy/intolerance/contraindication, OR combination therapy AND A1C >=7.5%. Continuation requires stable maintenance >=3 months AND demonstrated A1C reduction (approval period 36 months). Aetna Medicare Part D plans cover Mounjaro for type 2 diabetes (NOT for off-label weight loss). Quantity limits: 4 single-dose pens or vials (2 mL) per 21 days OR 12 single-dose pens or vials (6 mL) per 63 days.

Question 5

Does Aetna cover Foundayo (orforglipron)?

Accepted Answer

Aetna had not published a primary-source PA bulletin for Foundayo (orforglipron) on aetna.com as of 2026-05-09 — FDA approval was 04/01/2026 and Aetna's bulletin update cadence has not yet incorporated it. Coverage is currently determined at the plan/employer level. Where covered, expect criteria to mirror the Wegovy 4774-C framework (BMI >=30 or >=27 with comorbidity, 6-month comprehensive weight-management program, 5% continuation). For Aetna Medicare Part D members, all Foundayo formulations are included in the CMS Medicare GLP-1 Bridge at $50/month flat copay beginning 07/01/2026 through 12/31/2027 for members with BMI >=27 plus heart disease or prediabetes. Re-verify Aetna primary source quarterly.

Question 6

Does Aetna cover Saxenda (liraglutide)?

Accepted Answer

Aetna covers Saxenda (liraglutide for chronic weight management) per bulletin 1227-C P08-2024_R (12/19/2024). Adult criteria: BMI >=30, or BMI >=27 with at least one weight-related comorbid condition (verbatim list: hypertension, type 2 diabetes mellitus, or dyslipidemia), AND participation in a comprehensive weight-management program (behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up) for at least 6 months prior to drug therapy. Pediatric (12-17): BMI corresponding to >=30 kg/m^2 for adults by international cut-offs (Cole Criteria) + 6-month program. CRITICAL DIFFERENCE FROM WEGOVY/ZEPBOUND: Saxenda continuation requires loss of >=4% of baseline body weight (NOT 5%), or maintained 4% loss. Pediatric continuation requires >=1% reduction in BMI from baseline. Saxenda is NOT included in the CMS Medicare GLP-1 Bridge effective 07/01/2026. Quantity limits: 15 mL (1 package of five 3 mL pens) per 25 days; 45 mL (3 packages) per 75 days.

Question 7

What's the copay for GLP-1 medications with Aetna?

Accepted Answer

When Aetna does cover a GLP-1, the typical patient copay is $25-$80 per month. Prior authorization is almost always required, and many plans also require step therapy through metformin or another diabetes medication first.

Question 8

How do I appeal a Aetna GLP-1 denial?

Accepted Answer

If Aetna denies your GLP-1 prescription, you have the right to appeal. Steps: (1) request the written denial letter and the specific clinical criteria, (2) ask your prescriber to submit a Letter of Medical Necessity citing BMI, comorbidities, and prior failed weight-loss attempts, (3) file a formal appeal within the deadline (usually 60-180 days), (4) escalate to an external review if denied again. Many denials are overturned on appeal with proper documentation.

Question 9

What if I can't get Aetna to cover GLP-1?

Accepted Answer

If your appeal is denied, the most affordable cash-pay option is compounded semaglutide or tirzepatide through telehealth providers. Monthly costs typically range from $149-$299 for compounded GLP-1s versus $1,000-$1,350 for brand-name medications. Top providers serving denied patients include Hims, Ro, Found.

Does Aetna Cover GLP-1 Medications? (2026)

Coverage by Medication^[8]

If You're Denied by Aetna

Top Compounded Alternatives

Boston Medical Group

Found

Hims

LaSara Medical Group

LillyDirect Foundayo

myRocky

Ro

Roen Rx

RxPros

Sprout Health

Frequently Asked Questions

Glossary references

Aetna Coverage Updates

Medication	Aetna Coverage
Wegovy (semaglutide)	Aetna covers Wegovy on Non-Medicare commercial plans under bulletin 4774-C UDR 08-2023 v2 (effective 05/01/2024). Adult initial criteria: patient must be >=18, have BMI >=30 (or BMI >=27 with one weight-related comorbidity), and have participated in a comprehensive weight-management program for at least 6 months prior to drug therapy. Initial approval is 7 months; continuation/reauthorization is 12 months and requires documented loss of at least 5% of baseline body weight (or maintained 5% loss). Pediatric (12-17): BMI in the 95th percentile or greater + 6-month program. Wegovy also has a separate cardiovascular risk-reduction pathway in 4774-C for patients with established CVD on guideline-directed management and therapy who do NOT have type 2 diabetes. CVS Caremark (Aetna's PBM, both CVS Health subsidiaries) designated Wegovy the PREFERRED commercial GLP-1 in July 2025 — most Aetna commercial books now step toward Wegovy. Quantity limits: 0.25-1 mg = 2 mL per 21 days; 1.7-2.4 mg = 3 mL per 21 days.
Ozempic (semaglutide)	Aetna covers Ozempic for type 2 diabetes per bulletin 2439-C UDR 05-2024 (last reviewed 10/27/2024). Initial PA requires the patient is NOT on stable GLP-1 maintenance >=3 months AND meets one of: (1) inadequate response, intolerance, or contraindication to metformin; (2) requires combination therapy AND has A1C >=7.5%; (3) eGFR <30 mL/min/1.73m^2; or (4) established cardiovascular disease. Continuation requires stable maintenance >=3 months AND demonstrated A1C reduction since starting GLP-1 therapy. Aetna Medicare Part D plans cover Ozempic for type 2 diabetes (NOT for off-label weight loss). Quantity limits vary by strength: 2 mg/1.5 mL = 1 pen per 21 days; 4 mg/3 mL and 8 mg/3 mL = 1 pen per 21 days. Verbatim MACE language in the bulletin: 'reduce the risk of major adverse cardiovascular events…in adults with type 2 diabetes mellitus and established cardiovascular disease.'
Zepbound (tirzepatide)	Aetna covers Zepbound on Non-Medicare commercial plans per bulletin 6947-C P04-2025 (effective 07/01/2025), which supersedes the older 6192-C. Adult criteria: BMI >=30 OR BMI >=27 with one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia), plus participation in a comprehensive weight-management program for at least 6 months prior to drug therapy. Continuation requires documented >=5% baseline body-weight loss. Separate OSA pathway covers moderate-to-severe OSA in adults with obesity (AHI >=15 events/hour). CRITICAL CAVEAT: a separate Zepbound Exception bulletin 6981-A P04-2025 applies on plan-formulary codes ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC where Wegovy is the preferred step. CVS Caremark removed Zepbound from MOST commercial formularies effective July 2025 in favor of Wegovy as the single preferred GLP-1, so many Aetna commercial members now see Zepbound denials they did not see in 2024. Aetna Medicare Part D does NOT cover Zepbound for weight loss (statutory exclusion); may cover for OSA indication. Beginning 07/01/2026, only the Zepbound KwikPen formulation (NOT vials/single-dose pens) is available to MA-PD members via the CMS Medicare GLP-1 Bridge. Quantity limits all strengths: 2 mL (1 package of 4 pens) per 21 days; 6 mL (3 packages of 4 pens) per 63 days.
Mounjaro (tirzepatide)	Aetna covers Mounjaro for type 2 diabetes per bulletin 5468-C UDR 05-2024 (last reviewed 10/27/2024). Initial PA verbatim: 'The patient has NOT been receiving a stable maintenance dose of the requested drug for at least 3 months and ONE of the following criteria are met' — either metformin inadequacy/intolerance/contraindication, OR combination therapy AND A1C >=7.5%. Continuation requires stable maintenance >=3 months AND demonstrated A1C reduction (approval period 36 months). Aetna Medicare Part D plans cover Mounjaro for type 2 diabetes (NOT for off-label weight loss). Quantity limits: 4 single-dose pens or vials (2 mL) per 21 days OR 12 single-dose pens or vials (6 mL) per 63 days.
Foundayo (orforglipron)	Aetna had not published a primary-source PA bulletin for Foundayo (orforglipron) on aetna.com as of 2026-05-09 — FDA approval was 04/01/2026 and Aetna's bulletin update cadence has not yet incorporated it. Coverage is currently determined at the plan/employer level. Where covered, expect criteria to mirror the Wegovy 4774-C framework (BMI >=30 or >=27 with comorbidity, 6-month comprehensive weight-management program, 5% continuation). For Aetna Medicare Part D members, all Foundayo formulations are included in the CMS Medicare GLP-1 Bridge at $50/month flat copay beginning 07/01/2026 through 12/31/2027 for members with BMI >=27 plus heart disease or prediabetes. Re-verify Aetna primary source quarterly.
Saxenda (liraglutide)	Aetna covers Saxenda (liraglutide for chronic weight management) per bulletin 1227-C P08-2024_R (12/19/2024). Adult criteria: BMI >=30, or BMI >=27 with at least one weight-related comorbid condition (verbatim list: hypertension, type 2 diabetes mellitus, or dyslipidemia), AND participation in a comprehensive weight-management program (behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up) for at least 6 months prior to drug therapy. Pediatric (12-17): BMI corresponding to >=30 kg/m^2 for adults by international cut-offs (Cole Criteria) + 6-month program. CRITICAL DIFFERENCE FROM WEGOVY/ZEPBOUND: Saxenda continuation requires loss of >=4% of baseline body weight (NOT 5%), or maintained 4% loss. Pediatric continuation requires >=1% reduction in BMI from baseline. Saxenda is NOT included in the CMS Medicare GLP-1 Bridge effective 07/01/2026. Quantity limits: 15 mL (1 package of five 3 mL pens) per 25 days; 45 mL (3 packages) per 75 days.
Typical copay (when covered)	$25-$80 / month